Fundraising FoxThiogenesis Therapeutics
Toronto, US · Founded 2018 · Ontario, Canada corporation
Find your way into Thiogenesis Therapeutics
187 people in our graph share verified history with the Thiogenesis Therapeutics team — schools, employers, funds. One of them is your warm intro.
Tracy Tidyunlockedknows Brook G. Riggins · together at Canaccord Genuity - Global Capital Markets (overlapped)
knows the team · via Canaccord Genuity - Global Capital Markets
×10knows the team · via University of British Columbia
Thiogenesis Therapeutics is a clinical-stage biopharmaceutical company developing sulfur-based therapeutic compounds to treat oxidative stress and inflammation in mitochondrial diseases. The company is advancing TTI-0102, a novel cysteamine prodrug candidate, for rare inherited and acquired mitochondrial disorders including nephropathic cystinosis and Leigh syndrome.
Founders & leadership
Thiogenesis Therapeutics was founded in 2018 by Patrice Rioux and Dr. Rioux.
PR
Patrice RiouxCo-founder
DR
Dr. RiouxCo-founder, Director and Chief Executive Officer
BG
Brook G. RigginsExecutiveBrook G. Riggins is an executive officer and director at Thiogenesis Therapeutics, a clinical-stage biopharmaceutical company. He has prior experience in venture capital and private equity with expertise in equity research, portfolio management, and corporate finance, and holds an MBA in Finance from York University.
NA
Neil A. JohnsonExecutiveNeil A. Johnson is an executive with finance and operations experience, including leadership roles in financial planning and analysis, strategic planning, manufacturing finance, and M&A support across corporate and divisional levels.
Board
WH
W. Hogan MullallyBoard director
CS
Christopher StarrBoard director
KT
Kim TsuchimotoBoard director
DS
Dr. StarrChairman
Reported raises · per SEC filings
Form D private placements$877.8K disclosed across 5 rounds · 2021–2026
▶$29KraisedJun 2026 · BiotechnologyRule 506(b)
▶$29KraisedJun 2026 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrice RiouxExecutive Officer, Director
- W. Hogan MullallyDirector
- Kim TsuchimotoDirector
- Brook G. RigginsExecutive Officer, Director
- Christopher StarrDirector
- Offering amount
- $29K
- Amount sold
- $29K
- First sale
- Jun 2026
- Incorporated
- Corporation, Ontario, Canada
- Federal exemptions
- 06b
▶$125.5KraisedAug 2025 · OtherRule 506(b)
▶$125.5KraisedAug 2025 · Other
Rule 506(b)Officers, directors & promoters on the filing
- Patrice RiouxExecutive Officer, Director
- W. Hogan MullallyDirector
- Brook G. RigginsExecutive Officer, Director
- Christopher StarrDirector
- Kim TsuchimotoDirector
- Offering amount
- $125.5K
- Amount sold
- $125.5K
- First sale
- Jul 2025
- Incorporated
- Corporation, Ontario, Canada
- Federal exemptions
- 06b
▶$252.3KraisedDec 2023 · 1 investors · OtherRule 506(b)
▶$252.3KraisedDec 2023 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Kim TsuchimotoDirector
- Patrice RiouxExecutive Officer, Director
- Christopher StarrDirector
- W. Hogan MullallyDirector
- Brook G. RigginsExecutive Officer, Director
- Offering amount
- $252.3K
- Amount sold
- $252.3K
- First sale
- Dec 2023
- Incorporated
- Corporation, Ontario, Canada, 2018
- Federal exemptions
- 06b
▶$218.3KraisedNov 2022 · 3 investors · OtherRule 506(b)
▶$218.3KraisedNov 2022 · 3 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Hogan W. MullallyDirector
- Kim TsuchimotoDirector
- Patrice RiouxExecutive Officer, Director
- Brook RigginsExecutive Officer, Director
- Christopher StarrDirector
- Offering amount
- $218.3K
- Amount sold
- $218.3K
- First sale
- Nov 2022
- Incorporated
- Corporation, Ontario, Canada, 2018
- Federal exemptions
- 06b
▶$252.8KraisedAug 2021 · 2 investors · OtherRule 506(b)
▶$252.8KraisedAug 2021 · 2 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Neil A. JohnsonExecutive Officer, Director
- W. Hogan MullallyDirector
- Brook G. RigginsExecutive Officer, Director
- Offering amount
- $252.8K
- Amount sold
- $252.8K
- First sale
- Jul 2021
- Incorporated
- Corporation, Ontario, Canada, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Thiogenesis Therapeutics do?
- Thiogenesis Therapeutics is a clinical-stage biopharmaceutical company developing sulfur-based therapeutic compounds to treat oxidative stress and inflammation in mitochondrial diseases. The company is advancing TTI-0102, a novel cysteamine prodrug candidate, for rare inherited and acquired mitochondrial disorders including nephropathic cystinosis and Leigh syndrome.
- Who founded Thiogenesis Therapeutics?
- Thiogenesis Therapeutics was founded by Patrice Rioux, Dr. Rioux in 2018.
- How much funding has Thiogenesis Therapeutics raised?
- Thiogenesis Therapeutics has disclosed $877.8K raised across 5 rounds.
- Where is Thiogenesis Therapeutics headquartered?
- Thiogenesis Therapeutics is headquartered in Toronto, US.